United Kingdom (UK)
Recombinant monoclonal antibody to IL-1B. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma IC8.
UniProt Accession Number of Target Protein: P01584
Alternative Name(s) of Target: IL1B; IL-1β; 1L1F2; Interleukin-1 beta; IL-1 beta; Catabolin; 1C8
Immunogen: The original mouse antibody was generated by immunizing mice with human IL-1B protein. The humanized version was generated by grafting CDRs of the original mouse antibody onto human framework regions.
Specificity: This antibody binds human Interleukin-1 beta, which is a potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production. It promotes Th17 differentiation of T-cells and synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells. It also plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6.
Application Notes: This antibody is the humanized version of original mouse antibody IC8. This antibody binds human IL-1B with a binding affinity of Kd= 0.28 nM. The Fab version of this antibody was reported to neutralize IL-1B activity both in an in vitro and an in vivo assay (US7608694).
Antibody first published in: PMID: